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those without on PCS and SF-6D, but not MCS. This suggests that SF-12v2 can aid 
in quantifying HRQL benefits from interventions that may reduce ER/hospital uti-
lization in adults with CF.
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Objectives: The Assessment of Burden of COPD (ABC) tool evaluates and visualizes 
the health status of patients with chronic obstructive pulmonary disease (COPD). 
This tool may be used during consultations to monitor the burden of COPD and to 
adjust treatment. The ABC tool has items in 5 dimensions: symptoms, limitations, 
mental status, exacerbations, and fatigue. The aim of our study was to determine 
the burden of each of 15 elements in the ABC questionnaire. MethOds: A discrete 
choice experiment (DCE) was conducted using telephone-assisted personal inter-
views with 279 COPD patients. They were presented 13 sets of two patients, and 
decided which patient was in the worst health state. In order to make the choice 
task feasible despite the large number of 15 attributes, we generated an efficient 
partial profile design, that kept attributes in some dimensions constant and all at 
the same level (fold in), while varying the attributes in other dimensions (fold out). 
This reduced the burden on respondents by having them assess some attributes 
combined in categories, instead of as separate attributes. Multinomial logit was 
used to analyze the data. Results: Patients were considered to be in worst health 
if they had high levels of fatigue, exacerbations, anxiety, breathlessness at rest and 
limitations in moderate physical activities. These factors had three to five times 
as much impact on the burden of disease as lower levels of these attributes and 
other limitations. Coefficients were very small and/or statistically insignificant for 
breathlessness during physical activity, limitations on strenuous activity, coughing, 
small numbers of exacerbations, and most mental attributes. cOnclusiOns: It is 
possible to administer cognitively complicated DCE questionnaires using a fold-in-
fold-out design. COPD-patients seem to accept being unable to perform strenuous 
activities. Gains in well-being can primarily be achieved by focusing on patients’ 
ability to lead a relatively normal everyday life.
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Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease. 
EQ-5D utilities, an important consideration for cost-effectiveness analysis, are 
not commonly reported in IPF clinical trials. On the other hand, the St George’s 
Respiratory Questionnaire (SGRQ) is the most extensively used patient reported 
outcome measure in IPF patients. The objective of this study was to develop a 
mapping algorithm from the total SGRQ score to obtain EQ-5D utilities. MethOds: 
Data were analysed from a double-blind multicentre study conducted in England 
and Wales of which 181 IPF patients received either co-trimoxazole or placebo. 
In total, 202 pairs of data were collected recording both SGRQ and the EQ-5D-3L. 
Generalised mixed models, accounting for repeated measurements within 
subjects as residual or generalised random effects, were fit to the data. Explanatory 
variables were evaluated to aid model fit: Age; BMI; Sex; Forced Expiratory Volume 
in 1 second (FEV1); Forced Vital Capacity (FVC); and FEV1/FVC. Additionally, the 
potential non linearity of the relationship between explanatory and response 
variables was explored by investigating transformations and fitting restricted 
cubic splines with 4 knot points. Goodness of fit statistics determined the best 
fitting model. Results: The generalised random effects model was the best fit-
ting model. The addition of explanatory variables, use of transformations and 
investigation of a restricted cubic spline did not improve model fit. The final map-
ping algorithm, EQ-5D = 1.3246 – 0.01276*SGRQ, was associated with a root mean 
squared error of 0.1391. Inspection of the scatter plot showed that EQ-5D utili-
ties predicted by the mapping algorithm closely approximated observed values 
from the study. cOnclusiOns: A mapping algorithm was developed to estimate 
EQ-5D utilities from the total SGRQ score in IPF patients. This may be useful for 
researchers conducting cost-effectiveness analysis when EQ-5D utilities are not 
available from IPF clinical trials.
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Objectives: Chronic obstructive pulmonary disease (COPD) is one of the most 
common and burdensome chronic respiratory diseases. This pilot study aimed 
to explore the priorities of patients with moderate-to-severe COPD in relation 
to treatment. MethOds: Interviews were conducted with 20 patients with self-
reported moderate-to-severe COPD. Patients completed a brief best-worst scaling 
(BWS) exercise comprising 12 questions in which 15 features (benefits, harms, 
or administration features of a COPD treatment) were presented in sets of 5. On 
each question, patients indicated the most important and the least important 
feature when choosing whether to take a treatment. Frequency counts of features 
selected as the most or least important were used to generate BWS weights for 
each feature. BWS weights ranged from –1 to +1, with a positive weight reflecting 
greater importance. Results: The sample consisted of 11 males and 9 females, 
whose age range was 48 to 86 years (median: 65 years). BWS weights showed that 
the most important features were improved ability to perform daily activities 
Objectives: Patients with allergic asthma not well controlled on pharmacotherapy 
constitute a significant cost to society, whilst having reduced quality of life. Allergy 
immunotherapy tablets for sublingual administration (SLIT-tablets) have been devel-
oped as an effective, well tolerated and convenient treatment modality, suitable for 
home treatment. The purpose of this analysis was to investigate cost-effectiveness 
of the SQ® HDM SLIT-tablet in a population with allergic asthma that is not well 
controlled, despite use of pharmacotherapy. MethOds: A multicentre, double-
blind, randomised, placebo-controlled clinical trial with the SQ® HDM SLIT-tablet 
(ClinicalTrials.gov: NCT01433523) has shown statistically significant improvements 
for all efficacy endpoints in allergic asthma, including improvement in health-
related quality of life. A cost-utility analysis was performed using a decision tree 
structure and data taken from the SQ® HDM SLIT-tablet clinical trial, including 
SF-36 and health care utilisation data. Long-term efficacy data was limited, and 
therefore conservative assumptions were adopted, framed by expert advice. As basis 
for the analysis, German preference weights and costs were applied and a 9-year 
time horizon adopted. Uncertainty around efficacy assumptions was explored by 
sensitivity analyses. Results: The SQ® HDM SLIT-tablet was cost-effective com-
pared with pharmacotherapy, in the treatment of allergic asthma (ICER< 15,000 € /
QALY). During sensitivity analysis, model results were sensitive to changes in input 
parameters, particularly in relation to long-term effectiveness. This indicates the 
importance of establishing long-term outcomes following treatment with the SQ® 
HDM SLIT-tablet. cOnclusiOns: In the base case analysis, SQ® HDM SLIT-tablet 
proved to be cost-effective in the treatment of allergic asthma, compared to placebo. 
Conservative efficacy assumptions were adopted for the analysis, and therefore, the 
true benefits of the treatment may be underestimated.
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Objectives: Anaphylaxis is a severe, often life-threatening, allergic reaction (com-
monly to foods, insect stings, and medications), frequently requiring immediate 
medical attention. This study examined recent trends of anaphylaxis-related hos-
pitalization in the United States (US). MethOds: Study data were drawn from the 
Healthcare Cost and Utilization Project’s 2001-2012 National (Nationwide) Inpatient 
Samples (NIS), a nationally representative database of hospital discharges in the 
US. Anaphylaxis-related hospitalizations were identified using a modification 
of a previously published algorithm (Walsh et al, 2013); this algorithm evaluates 
diagnosis codes on each record to identify anaphylaxis-related hospitalizations. 
In addition to quantifying the rate of hospitalization (per 100,000 US population), 
length of stay (LOS) and total costs for such hospitalizations were evaluated. Overall 
estimates, as well as by age group, were generated. Results: Across all age groups, 
the rate of anaphylaxis-related hospitalizations increased by ~62% between 2001 
and 2012, from 2.4/100,000 US population in 2001 to 3.8/100,000 in 2012. In gen-
eral, annually the greatest rate was among those 65-84 years old, although the 
greatest rate observed was for those 85+ years in 2012, at 8.0/100,000, with rates 
among this age group steadily increasing over time. Among all anaphylaxis-related 
hospitalizations, the mean total cost (in 2014 US dollars) increased by more than 
55%, from $12,508 in 2001 to $19,420 in 2012. The mean LOS across all anaphylaxis-
related hospitalizations increased by > 1 full day, from 3.7 days in 2001 to 4.9 days 
in 2012. cOnclusiOns: Since the early 2000s, rates of anaphylaxis-related hospi-
talization in the US have increased, with the mean LOS and cost per stay increasing 
as well. Healthcare decision makers should be aware of these data as they plan for 
allocation of resources used to treat anaphylaxis.
ReSPiRAtoRy-RelAted diSoRdeRS – Patient-Reported outcomes & Patient 
Preference Studies
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Objectives: Compare generic health-related quality of life (HRQL) between adults 
with and without cystic fibrosis (CF) to assess disease burden and to evaluate 
whether HRQL varies by level of health resource utilization (HRU) among adults with 
CF. MethOds: Analysis sample included adult respondents to the 2013 National 
Health and Wellness Survey from the EU5 countries (France, Germany, Italy, Spain 
and UK) and the US. We measured HRQL using the Short Form (SF)-12v2 and its 
derived utility index, the SF-6D; we measured HRU using self-reported frequency of 
hospital/emergency room (ER) visits over the preceding 6 months. Analysis of vari-
ance models compared mean HRQL scores of CF versus non-CF respondents (non-
CF mean scores were weighted to match the CF group’s age and sex distributions). 
Mann-Whitney tests assessed differences in HRQL between CF respondents with 
0 (No ER/Hospitalization) versus ≥ 1 ER/hospital visits (Any ER/Hospitalization). We 
calculated Cohen’s d effect sizes (ES) to describe the magnitude of between-group 
differences in mean HRQL scores. Results: Seventy-nine of 75,000 US and 109 
of 62,000 EU5 respondents self-reported CF. Mean scores were lower for CF versus 
non-CF respondents for all HQRL domains (P< 0.001); differences in physical (PCS) 
and mental component summaries (MCS) and SF-6D scores had ES of 0.66, 0.55, 
and 0.77, respectively. Mean scores of CF respondents with Any ER/Hospitalization 
were lower than mean scores of CF respondents with No ER/Hospitalization for 
PCS (P< 0.001; ES= 0.67) and SF-6D (P< 0.001; ES= 0.58), while MCS scores were com-
parable (P= 0.713; ES= 0.16). cOnclusiOns: Results indicate a substantial burden 
of CF disease on both mental and physical HRQL. Furthermore, within adults with 
CF the SF-12v2 can discriminate between those with ER/hospital utilization versus 
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databases MEDLINE, EMBASE and PubMed from January 2000 to February 10th, 
2015. To be eligible, studies had to focus on asthmatic patients, include pulmo-
nary or eosinophil measurements, and quality of life data. Results: The review 
allowed retrieving 5,776 studies and 42 fulfilled the eligibility criteria. Twenty-five 
articles presented a correlation coefficient between lung function and quality 
of life. All, except one, conclude to a positive correlation between lung function 
and quality of life with R-values ranging from 0.008 to 0.790. Of the 25 studies, 
36% obtained an R-value of 0.4 and over, indicating a weak to moderate correla-
tion. Sixteen of these results were statistically significant. One article evaluated 
the correlation between sputum eosinophil levels and AQLQ and concluded to a 
non-statistically significant correlation with an R-value of -0.15. Fourteen articles 
did not evaluate the direct correlation between the parameters of interest but pre-
sented raw data of these parameters. Of these, 12 studies presented data that indi-
cate a correlation between FEV1 and quality of life with an increase in quality of 
life score, when FEV1 increases. cOnclusiOns: The correlation coefficients found 
in the systematic review indicate that when lung function improves, and possibly 
when sputum eosinophil decreases, the quality of life improves. Furthermore, 
non-correlation studies that look at the same parameters support this 
hypothesis.
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Objectives: Idiopathic Pulmonary Fibrosis is a rare fatal respiratory disease char-
acterized by a decline in lung function leading to deliberating limitations on activity 
which may negatively impact health-related quality of life. There is limited research 
on the outcome measures of IPF. Systematically reviewed all the outcome measures 
used in the treatment of IPF and critically appraise the measures used to evaluate 
the treatment result of IPF with the aim of drawing conclusions regarding the suit-
ability of these measures. MethOds: Conducted a systematic review from Medline, 
EMBASE, EBM reviews, NICE, HTA written in English between 2008 and September 
2014. Data was extracted from the citation applying efficacy, safety and health-
related quality of life outcomes in the selected studies. Results: Lung function test 
is the most commonly used outcome measures. Exercise capacity and health-related 
quality of life are the secondly common outcomes used. Then mortality or acute 
exacerbation are the third most commonly used outcome measures. Dysponea 
and health related quality of life measures have at least two scales of measures 
used at the same time. Each of the measurements are used either alone or in com-
bination. The scale of measurement of mortality, survival, acute exacerbation vary 
accordingly. Mortality and survival are the most important outcomes to evaluate 
the efficacy of the treatment. Some studies used both of the mortality and survival, 
some used either one. cOnclusiOns: The appropriate outcome measures in IPF are 
lung function test as Forced Vital Capacity 10% relative change at one year, exercise 
capacity 6-MWT with saturation measures, St. George’s Respiratory Questionnaire 
along with SF-36. Overall survival combines with progression-free survival represent 
important treatment targets in IPF. All these measures are suitable and essential 
measures should be considered when investigating the new therapies. Assessing 
dysponea scale with UCSD and HRCT scanning are appropriate but not necessary 
outcome measures.
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Objectives: This study aimed to assess the health related quality of life of TB 
patients in Quetta. MethOds: A cross-sectional study was conducted to assess 
the health related quality of life by administering a pre-validated question-
naire based on European Quality of Life scale EQ-5D was used to measure health 
related quality of life. Convenient sampling was used for gathering data along 
with facilitator to help and guide respondents who faced difficulty in filling it. 
SPSS 17 was used for Descriptive analysis to demonstrate patients’ demograph-
ics. Inferential statistics (Mann-Whitney and Kruskal Wallis test, p< 0.05) were 
used to evaluate the significance of study. Results: The study population is 
dominated (55% )with females and mean age of respondents was 34.85 13 years. 
Majority (57%) of respondents were single and (86%) having urban residency. The 
mean EQ-5D descriptive score and EQ-VAS score were 0.53 0.22 and 64.84 15.7 
respectively. The EQ-5D and EQ-VAS scores were influenced by demographic char-
acteristics education level, occupation and income. cOnclusiOns: This study 
revealed that health related quality of life in TB patients is Lower and EQ-5D (util-
ity) scores were lowers as compared to EQ-VAS (perceived) scores. Respondents 
education level, occupation and income have impact on health related quality 
of life.
ReSPiRAtoRy-RelAted diSoRdeRS – health Care use & Policy Studies
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Objectives: This study aimed to evaluate the level of knowledge and aware-
ness of asthma among private and government schoolsteachers in urban area 
of Quetta. MethOds: A cross-sectional study was conducted to assess thelevel 
of knowledge and awareness of asthma among teachers of 12 different schools 
by administering a pre-validated questionnaire which was developed in English 
(0.49), lung function (0.44), and shortness of breath (0.43). These three features 
were chosen as the most important in more than 40% of their presentations. Being 
able to walk further and/or for longer was selected as the most important feature 
in 33.8% of presentations but the overall BWS weight (0.18) was low because the 
feature was selected as least important in 16.3% of presentations. Explanations 
given for the importance of benefit features often were interrelated, suggesting 
dependency between such outcomes. The least important features were needing 
a blood test before starting medication (–0.58) and mild skin reaction at injec-
tion site (–0.51). cOnclusiOns: Positive clinical outcomes were prioritised over 
harms or administration features of a treatment in this sample. Patients may not 
differentiate between breathing symptoms and functional ability when evaluat-
ing treatments.
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Objectives: Asthma is one of the most common and burdensome chronic res-
piratory diseases. This pilot study aimed to explore the priorities of patients with 
severe asthma in relation to treatment. MethOds: Interviews were conducted 
with 20 patients with self-reported severe asthma. Patients completed a brief 
best-worst scaling (BWS) exercise comprising 12 questions in which 17 features 
(benefits, harms, or administration features of an asthma treatment) were pre-
sented in sets of 5. On each question, patients indicated the most important and 
the least important feature when choosing whether to take a treatment. Frequency 
counts of features being selected as the most or least important were used to 
generate BWS weights for each feature. Weights ranged from –1 to +1, with a 
positive weight reflecting greater importance. Results: The sample consisted 
of 6 males and 14 females, whose age range was 23 to 60 years (median: 38 years). 
BWS weights showed that the most important features were improved shortness 
of breath (0.33), improved lung function (0.33), and halving the number of moder-
ate asthma attacks (0.27). These features were chosen as the most important in 
more than 25% of their presentations. Intravenous administration every 4 weeks, 
halving the number of severe attacks, and self-injection every 2 to 4 weeks also 
were selected as most important in more than 25% of presentations but the over-
all BWS weights were relatively low (less than 0.20) because these features were 
selected as least important in more than 15% of presentations. The least impor-
tant features were mild skin reaction at injection site (–0.71) and needing a blood 
test before starting medication (–0.63). cOnclusiOns: This sample of patients 
with asthma prioritised improved breathing, lung function, and reduced moder-
ate asthma attacks over potential harms or administration features. There was 
significant heterogeneity in preferences for individual features.
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Objectives: To determine which patient-reported outcome (PRO) tools were used 
in studies on respiratory diseases published in 2014. MethOds: An evidence sur-
veillance process was established based on a systematic search of PubMed, incor-
porating all studies published from 2010 and updated weekly, with a final search 
on 18 May 2015. Abstracts identified by the search that reported quality of life out-
comes in respiratory disorders were identified, based on ICD-10 classifications. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified from the 
abstract alone, where possible. Results: The search identified 1,980 articles pub-
lished in 2014, 1713 of which met the inclusion criteria. Of these, 171 (10%) were in 
respiratory disorders. Overall, 90 different PRO or clinician-reported instruments 
were used across 23 diseases, with 65 articles citing more than one tool. The most 
commonly researched diseases were COPD (60 articles), asthma (36), allergic rhinitis 
or rhinosinusitis (26), obstructive sleep apnoea (8) and bronchiectasis and cystic 
fibrosis (7 each). The St. George’s Respiratory Questionnaire (SGRQ) was the most 
commonly used PRO tool, in studies of COPD, asthma, bronchiectasis and emphy-
sema (36 articles), followed by the Asthma Quality of Life Questionnaire (13) and 
the Rhinoconjunctivitis Quality of Life tool (10). Utilities were measured in only 3 
studies, with SF-36 used twice and EQ-5D once. The PRO used was not specified in 
46 article abstracts: 20 of the 129 primary research articles, 3 of 7 study protocols 
and 23 of 35 systematic reviews. cOnclusiOns: COPD and asthma were the most 
widely researched respiratory diseases in 2014, with the SGRQ the most widely used 
PRO. Utility values were rarely assessed directly, which, given the wide range of PRO 
tools used, provides a challenge to assessing and comparing cost-effectiveness of 
interventions across studies.
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Objectives: Asthma is an inflammation of the respiratory functions character-
ized by symptoms such as dyspnea, wheezing, sputum production and cough that 
can significantly affect quality of life. The objective of this review was to explore 
the evidence on the possible correlation between lung function (FEV1 or FVC or 
PEF) or eosinophil levels and quality of life in asthmatic patients. MethOds: A 
literature search was made using keywords such as “asthma”, “eosinophil”, “qual-
ity of life”, and “respiratory function”. The search was conducted in the electronic 
